Navigation Links
NCE in Biological Technology

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

...tory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) anti-inflammatory agent for the treatment of the signs and symptoms of osteoarth...

NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

...ory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs...

Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward

...OACH TO IMI PLANNED Under the terms of the agreement, Oslo Cancer Cluster nce with Cancer-Bio-Sante Cluster and Toulouse Canceropole commit to cooperate ...ion in Atlanta. More information: Bjarte Reve, CEO, Oslo Cancer Cluster nce - cellphone: +47-971-09-585. Jean-Pierre Saintouil, CEO, Toulouse Cancer-...

SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)

...ndent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced nce is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30...

New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)

...ion of new kinase inhibitors." Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to nce discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners." About IOTA IOTA Pharmaceuticals provid...

ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials

...efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This nce (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year. The objectives of Allergan and ExonHit's stra...

Midwest Investment Bank Piper Jaffray Resurges in New York City

... 505(b)(2) pathway receive Waxman-Hatch market exclusivity (equivalent to patent protection) for three years for new labeling, up to five years for an nce and seven years under orphan drug designation. While this is not of great interest to Big Pharma because market exclusivity is too short, it is of gre...
Other Tags
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
Other Contents